trending Market Intelligence /marketintelligence/en/news-insights/trending/SmKEhcn-9FiEhxX2M6J45A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Activist investor Caligan Partners reports 10% stake in AMAG Pharmaceuticals

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Activist investor Caligan Partners reports 10% stake in AMAG Pharmaceuticals

New York-based investor firm Caligan Partners LP disclosed a 10.3% stake in AMAG Pharmaceuticals Inc.

According to a Schedule 13D filed Aug. 15, Caligan Partners owns 3,499,428 common shares of the pharmaceutical company.

Meanwhile, Bloomberg News reported that the activist investor is looking to push changes at the company, including reshuffling the board, cost reductions and a renewed focus on the global expansion of AMAG's kidney drug business, citing people familiar with the matter.

Waltham, Mass.-based AMAG Pharmaceuticals is developing medicines for patients with complex, under-treated health conditions, such as anemia, pregnancy complications, women's sexual function and menopause-related issues.

The company booked total revenues of $78.1 million for the three months ended June 30, but incurred a net loss of $120.8 million.

In June, AMAG scored a U.S. Food and Drug Administration approval for Vyleesi, a medicine for treating generalized hypoactive sexual desire disorder, or HSDD, a condition characterized by low sexual desire in premenopausal women. The patients can inject the drug themselves as needed before sexual activity.

The company plans to launch Vyleesi in September.